THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

7th ImmunoTherapy of Cancer Conference
October 2 – 3, 2020 • Virtual Conference

SCIENTIFIC PROGRAM

www.itoc-conference.eu
The 7th Immunotherapy of Cancer Conference (ITOC7) to be held virtually from October 2 - 3, 2020 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC7 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the Society for Immunotherapy of Cancer (SITC), the German Cancer Consortium (DKTK) as well as the Comprehensive Cancer Center Munich (CCCM) in Munich. The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.
ITOC7 COMMITTEES

ITOC7 Conference Presidents

- Mario Sznol (Yale School of Medicine, New Haven, CT, United States)
- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

ITOC7 Chairmen of the Scientific Committee

- Volkmar Nuessler (TZM, Munich, Germany)
- Paolo Ascierto (Instituto Nazionale Tumori, Italy)

ITOC7 Scientific Committee

- Michael Bergmann (Medical University Vienna, Austria)
- Christian Blank (NKI, Netherlands)
- Lisa Butterfield (Parker Institute for Cancer Immunotherapy, United States)
- Tanja de Gruijl (Cancer Center Amsterdam, Amsterdam, The Netherlands)
- Samir N. Khleif (Georgetown University Medical Center, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Ohio State University, Columbus, OH, USA)
- Pedro J. Romero (University of Lausanne, Switzerland)
- José Saro (Avacta Life Sciences, United Kingdom)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Wenru Song (Kira Pharmaceuticals, United States)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
- Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
- Lei Zheng (Johns Hopkins University, Baltimore, MD)
- Christoph Zielinski (Medical University of Vienna, Austria)
LIVE TALKS - FRIDAY, OCTOBER 2, 2020

08.50 – 09.00  Welcome Addresses
Michael von Bergwelt, Mario Sznol

09.00 – 10.45  Session 1: Emerging Concepts / New Agents
Chair: Christoph Zielinski, Michael von Bergwelt

09.00 – 09.15  The CD47-SIRPα myeloid immune checkpoint in cancer
Timo K. van den Berg, Amsterdam, The Netherlands

09.15 – 09.30  Potential of ADAR Pathway in immunotherapy
Jeffrey Ishizuka, Boston, MA, USA

09.30 – 09.45  L1 - TGF-beta blocks type I IFN release and tumor rejection in spontaneous mammary tumors
Nadege Bercovici, Paris, France

09.45 – 10.00  L2 - In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific CD20-TCB antibody
Floriana Cremasco, Schlieren, Switzerland

10.00 – 10.15  CXCR3 required for anti-PD-1 efficacy
Andrew Luster, Boston, MA, USA

10.15 – 10.30  L3 - Update of the OpACIN and OpACIN-neo trials: 36-months and 18-months relapse-free survival after (neo) adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients
Judith Versluis, Amsterdam, The Netherlands

10.30 – 10.45  T cell bispecific antibodies (4-1BB and tumor antigen)
Pablo Umana, Zurich, Switzerland

10.45 – 11.15  Coffee Break

11.15 – 12.30  Session 2: Microbiome and immunotherapy
Chair: Dirk Haller, Nicola Segata

11.15 – 11.30  Microbiome and Immunotherapy in Cancer
Giorgio Trinchieri, Bethesda, MD, USA

11.30 – 11.45  Computational meta-genomics for uncovering the unexplored microbiome diversity
Nicola Segata, Trento, Italy

11.45 – 12.00  Microbial-derived metabolites in allo-transplant and anti-tumor immunity
Hendrik Poeck, Munich, Germany

12.00 – 12.15  Microbiome and epithelial cell stress in colon cancer
Dirk Haller, Munich, Germany

12.15 – 12.30  Microbiome modulation in HSC transplantation
Marcel van den Brink, New York, NY, USA

12.30 – 13.00  Satellite Symposium - See Page 18 for Details
LIVE TALKS - FRIDAY, OCTOBER 2, 2020

13.00 – 13.30 Lunch Break

13.30 – 15.00 Session 3: Tumor microenvironment
Chair: Jürgen Ruland, Eric Tartour

13.30 – 13.45 The role of the microbiome in modulating the efficacy of anti-PD-1 therapy
Vyara Matson, Chicago, IL, USA

13.45 – 14.00 Immunoscore as possible predictive marker of response to treatments
Franck Pagès, Paris, France

14.00 – 14.15 Tumor intrinsic vs tumor extrinsic immune suppression
Kai Wucherpfennig, Boston, MA, USA

14.15 – 14.30 Arming oncolytic viruses for DC activation and recruitment in melanoma
T.D. de Graaf, Amsterdam, The Netherlands

14.30 – 14.45 Dissecting the interplay between tumor cells and the immune system melanoma progression and response to therapy
Marisol Soengas, Madrid, Spain

14.45 – 15.00 Pancreatic Cancer Tumor Microenvironment
Lei Zheng, Baltimore, MD, USA

15.00 – 15.30 Coffee Break

15.30 – 16.15 Session 4: Vaccine Therapy
Chair: Barbara Seliger, Lei Zheng

15.30 – 15.45 Mucosal vaccinations for cancer treatment
Georg Stary, Vienna, Austria

15.45 – 16.00 Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma
Lisa Butterfield, San Francisco, CA, USA

16.00 – 16.15 Vaccine therapy in reversing anti-PD1 resistance
Samir Khleif, Washington, DC, USA

16.15 – 16.45 Session 5: Pro & Contra Session: Blinatumomab vs anti-CD19 CAR T cells: which treatment should be preferred and when? Can we treat with either regimen after relapse on the other?
Chair: Dominik Wolf, Hermann Einsele

16.15 – 16.30 Pro Bite
Dominik Wolf, Innsbruck, Austria

16.30 – 16.45 Pro CAR
Marion Subklewe, Munich, Germany
LIVE TALKS - FRIDAY, OCTOBER 2, 2020

16.45 – 17.15 Coffee Break

17.15 – 18.00 Session 6: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
Chair: Lisa Butterfield, José Saro

17.15 – 17.30 High dimensional Immune Monitoring of Clinical Trials to Advance Human Immunotherapy
Pier Federico Gherardini, San Francisco, CA, USA

17.30 – 17.45 Hyperprogressive disease in patients treated with Immune checkpoint inhibitors
Giuseppe Lo Russo, Milan, Italy

17.45 – 18.00 Identifying Breast Cancer Specific Isoforms
Jacques Banchereau, Bar Harbor, ME, USA
LIVE TALKS - SATURDAY, OCTOBER 3, 2020

08.30 – 09.00  Session 7: “Lost in Translation”
Chair: Philipp Beckhove, Hendrik Poeck

08.30 – 08.45  Ups and downs of IDO inhibition in cancer treatment
George Prendergast, Philadelphia, PA, USA

08.45 – 09.00  Why adoptive T cell therapies fail solid tumors?
Sebastian Kobold, Munich, Germany

09.00 – 09.30  Satellite Symposium - See Page 18 for Details

09.30 – 10.15  Session 8: Lifetime Achievement Award
Chair: Michael von Bergwelt

The 34th anniversary of interleukin 6, a major player in inflammation, autoimmunity and cancer
Toshio Hirano, Chiba, Japan

10.15 – 10.45  Coffee Break

10.45 – 11.45  Session 9: Cell Therapy in Solid Tumors
Chair: Per Thor Straten, Pedro Romero

10.45 – 11.00  Challenges of T-cell therapy in solid tumors
Cassian Yee, Houston, TX, USA

11.00 – 11.15  Novel CAR formats for solid tumors
Sidi Chen, West Haven, CT, USA

11.15 – 11.30  Novel strategies to enable T cell therapy of cancer
Per Thor Straten, Herlev, Denmark

11.30 – 11.45  CAR T cell therapy in non hematological pediatric cancer
Franco Locatelli, Rome, Italy

11.45 - 12.15  Satellite Symposium - See Page 19 for Details

12.15 – 12.45  Lunch Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.45 – 14.00</td>
<td>Session 10: Cell Therapy in Haematologic Diseases</td>
<td>Chair: Florian Bassermann, Hinrich Abken</td>
</tr>
<tr>
<td>12.45 – 13.00</td>
<td>Cell therapy of hematological malignancies</td>
<td>Chiara Bonini, Milan, Italy</td>
</tr>
<tr>
<td>13.00 – 13.15</td>
<td>New targets and technologies for CAR-T</td>
<td>Michael Hudecek, Würzburg, Germany</td>
</tr>
<tr>
<td>13.15 – 13.30</td>
<td>L4 - Synthetic agonistic receptor-activating BiTEs</td>
<td>Mohamed-Reda Benmebarek, Munich, Germany</td>
</tr>
<tr>
<td>13.30 – 14.00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>14.00 – 15.00</td>
<td>Session 11: Combination Therapy</td>
<td>Chair: Michael Bergmann, Samir Khleif</td>
</tr>
<tr>
<td>14.00 – 14.15</td>
<td>Combination of innate immune stimulation with immunity check point blockade for cancer therapy</td>
<td>Simon Heidegger, Munich, Germany</td>
</tr>
<tr>
<td>14.15 – 14.30</td>
<td>Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer</td>
<td>Marleen Kok, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>14.30 – 14.45</td>
<td>L5 - RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodies</td>
<td>Beatrice Thier, Essen, Germany</td>
</tr>
<tr>
<td>14.45 – 15.00</td>
<td>Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells</td>
<td>Claus Belka, Munich, Germany</td>
</tr>
<tr>
<td>15.00 – 15.15</td>
<td>Session 12: Best Poster Awards &amp; Closing Remarks</td>
<td>Chair: Volkmar Nüssler</td>
</tr>
</tbody>
</table>
ON-DEMAND TALKS

Tumor microenvironment
• 01 - Tumor lactic acidosis alters decisive T cell activities
  Angelika Fischbeck, Munich, Germany

Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
• 02 - Directly Linking Single T Cell Phenotype and Function to Genotype
  Yelena Bronevetsky, Emeryville, United States
• 03 - High-dimensional analysis of tumor architecture predicts cancer immunotherapy response
  Christian Schürch, Stanford, United States

“Lost in Translation”
• 04 - Mechanisms of lung cancer hyper-progression promoted by PD-1 immune checkpoint blockade
  Amaia Martinez-Usatorre, Lausanne, Switzerland

Young Researcher Session
• 05 - Deconstruction of hampered dendritic cell development by micro-environmental cross-talk in an organotypic human melanoma-in-skin model
  Marta Lopez Gonzalez, Amsterdam, The Netherlands

Combination Therapy
• 06 - Expression of anti-apoptotic gene cFLIP to enhance persistence in CAR T cells
  Grace Tan, North Dunedin, New Zealand
• 07 - A bispecific VHH approach to leverage the potent and widely applicable tumor cytolytic capacity of Vy9Vδ2 T cells
  Lisa King, Amsterdam, The Netherlands
• 08 - Gemcitabine induces pro-apoptotic BH3 only proteins and sensitizes pancreatic ductal adenocarcinoma cells for RLH-triggered immunogenic cell death
  Daniel Böhmer, Munich, Germany
P1 - Emerging concepts / novel agents

P01.01 - A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Atif Abbas, Hopkinton, United States

P01.02 - HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
Yan Asmann, Jacksonville, United States

P01.03 - VOC Pattern Recognition of Lung Cancer: a Comparative Evaluation of Different Dog- and eNose-Based Strategies Using Different Sampling Materials
Wiebke Biehl, Munich, Germany

P01.05 - Development of signal amplification for spatially-resolved, highly multiplexed biomarker analysis of human tumor tissues
Oliver Braubach, Menlo Park, United States

P01.06 - Spatially-resolved, highly multiplexed biomarker analysis of cancerous and normal human breast tissues.
Oliver Braubach, Menlo Park, United States

P01.08 - Beyond PD-1: Characterization of new checkpoints restricting function of cytotoxic lymphocytes infiltrating human carcinoma
Anna Herbstritt, München, Germany

P01.09 - Dual signalling protein 107 triggers innate and adaptive immune response towards tumour cells
Lisa Jacob, Groningen, Netherlands

P01.10 - IFNγ secretion of adaptive and innate immune cells as a parameter to display leukaemia derived dendritic cell (DCleu) mediated immune responses in AML
Lara Klauer, Munich, Germany

P01.11 - Role of Exosomes as promotors or biomarkers to study activation of leukemia-derived dendritic cells (DCleu)-mediated antileukemic activation of adaptive and innate immune-reactive cells against AML-blasts
Lin Li, Munich, Germany

P01.12 - Impact of complementary substances on immune cell activity
Martin Luzbetak, Munich, Germany

P01.13 - MERTK signaling is critical for T cell proliferation and memory
Richard Powell, Herlev, Denmark

P01.14 - Excessive biological ageing of circulating neutrophils in cancer promotes tumor progression
Christoph Reichel, Munich, Germany

P01.15 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-γamma IFN-γamma) signature - the DONIMI study
Irene Reijers, Amsterdam, Netherlands

P01.16 - Effects of the STAT3 inhibitors on senescent tumour cells
Olena Sapega, Prague, Czech Republic
POSTER PRESENTATIONS

P01.17 - Tim-3/Galectin-9 pathway controls the ability of malignant cells to escape host immune surveillance. Regulatory mechanisms and therapeutic targets
Vadim Sumbayev, Chatham Maritime, United Kingdom

P01.18 - Metabolic status and immune activation influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation
Sebastian Theurich, Munich, Germany

P01.20 - Tim-3-galectin-9 immunosuppressive pathway in human liquid and solid tumours
Inna Yasinska, Chatham Maritime, United Kingdom

P01.22 - Extending CAR T cell therapy applications via drug inducible control of transgene expression
Bettina Kotter, Bergisch Gladbach, Germany

P01.23 - Creating a cell-culture based reporter system for the evaluation of molecular signaling mechanisms of inhibitory chimeric antigen receptors
Maximilian Funk, Vienna, Austria

P01.24 - The selective HDAC6 inhibitor ITF3756 increases the differentiation to central memory T cells with reduced exhaustion phenotype
Gianluca Fossati, Cinisello Balsamo, Italy

P02 - Microbiome and immune system/immunotherapy

P02.01 - Predictive impact of the gut microbiota on treatment response to CD19 specific CAR T-cells
Viktoria Blumenberg, Munich, Germany

P02.02 - Generating neo- and self-antigen screening libraries for class II HLA presentation
Veronica Pinamonti, Heidelberg, Germany

P02.03 - Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
Martin Theilen, Köln, Germany

P03 - Tumor microenvironment

P03.01 - Prevalence of CD112R+ immune cells in normal lymphatic tissues, inflammation and the cancer microenvironment
Niclas Blessin, Hamburg, Germany

P03.02 - Suppression of T-cell proliferation and cytokine release by the adenosine axis are mediated by different mechanisms
Julia Festag, Planegg/Martinsried, Germany

P03.03 - Organization, function and gene expression of tertiary lymphoid structures in PDAC resembles lymphoid follicles in secondary lymphoid organs
María García-Márquez, Cologne, Germany
POSTER PRESENTATIONS

P03.04 - Applying Multispectral Unmixing and Spatial Analyses to Explore Tumor Heterogeneity with a Pre-Optimized 7-color Immuno-Oncology Workflow
Virgine Goubert, Marlborough, United States

P03.05 - Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors
Mathias Holpert, Seattle, United States

P03.06 - Pattern of Ki67+ expanding CD8+ cytotoxic T cells in healthy tissues, inflammation and the cancer microenvironment
Claudia Hube-Magg, Hamburg, Germany

P03.07 - Fast automated microfluidic-based multiplexed immunofluorescence for tumor microenvironment analysis
Alexandre Kehren, Lausanne, Switzerland

P03.08 - Prevalence and prognostic role of FoxP3<sup>+</sup> regulatory T lymphocytes in cancer. A tissue microarray study on >20’000 cancers
Tim Mandelkow, Hamburg, Germany

P03.11 - Exploring tumor-intrinsic factors regulating the recruitment of myeloid-derived suppressor cells (MDSC) in pancreatic ductal adenocarcinoma
Carlotta Rambuscheck, München, Germany

P03.12 - Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immune-oncology treatments
Suzanne Sitnikova, Cambridge, United Kingdom

P03.15 - Site-specific immune evasion and substantial heterogeneity within entities provide evidence for personalized immunotherapy
Martin Thelen, 50931, Germany

P03.17 - Functional Defects in B-cells of Patients with von-Hippel-Lindau Syndrome
Sebastian Theurich, Munich, Germany

P03.18 - uPA-PAI-1 heteromers promote advanced stages of breast cancer by attracting pro-tumorigenic neutrophils
Bernd Uhl, München, Germany

P03.20 - A murine, myc-driven lymphoma model expressing human CD22 enables testing of targeted therapies and their effects on tumor immune microenvironment
Fabian Müller, Erlangen, Germany

P03.21 - Projecting T cells into a reference transcriptomic atlas to interpret antitumor immune responses
Santiago Carmona, Epalinges, Switzerland

P03.22 - Repolarization of tumor-associated macrophages for immunotherapy of tumors with diverse major histocompatibility complex class I expression
Adrianna Piataková, Prague 2, Czech Republic
POSTER PRESENTATIONS

P03.23 - Evolution of the immune landscape within partially controlled murine melanoma
Chen Qing, London, United Kingdom

P03.26 - Immunoprofiling of oral and oropharyngeal tumours of different etiology
Barbora Pokrývková, Vestec, Czech Republic

P03.27 - Role of NOX2 for hypoxia-induced chemoresistance in acute myeloid leukemia
Sanchari Paul, Gothenburg, Sweden

P03.28 - Structural characteristics in tumor and lymph nodes as predictors of 3-year metastasis-free survival in surgically treated NSCLC
Laura Sellmer, Munich, Germany

P03.29 - Characterization of treatment-induced adaptive immune responses in pancreatic ductal adenocarcinoma
Jeannine Heetmeyer, München, Germany

P03.31 - Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
Natasa Prokopi, Amsterdam, Netherlands

P4 - Vaccine Therapy

P04.01 - Dendritic-cell based immunotherapy targeting pancreatic and NSCLC cancer stem cells
João Calmeiro, Coimbra, Portugal

P04.02 - A novel Cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies
Maria Hinterberger, Martinsried, Germany

P04.03 - Immune modulatory vaccine directed against IDO1-expressing immune cells elicits T cell-mediated anti-tumor immunity and enhances anti-PD1 responses
Ayako Pedersen, Copenhagen, Denmark

P04.04 - Multifunctional antibody construct for in vivo targeting of dendritic cells as a therapeutic vaccination strategy in AML
Saskia Schmitt, München, Germany

P04.05 - Modulating tumor microenvironment with arginase-1 specific T cells
Evelina Martinenaite, Copenhagen, Denmark

P04.06 - Mucosal immunization with a cDC1-targeted CTA1 adjuvant vaccine confers protection against melanoma metastasis
Mohammad Arabpour, Göteborg, Sweden

P04.08 - Virus like vaccines: a novel immunotherapy strategy against the cancer-associated endogenous retrovirus
Joana Daradoumis, Copenhagen, Denmark
POSTER PRESENTATIONS

P04.09 - Development of a dendritic cell vaccine against hepatocellular carcinoma using VSV-NDV
Julia Gold, München, Germany

P5 - Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

P05.01 - Comparative analysis of RNA versus DNA as input material for IGH repertoire sequencing panels for immuno-oncology applications and rare clone detection
Geoffrey Lowman, Carlsbad, United States

P6 - Cell Therapy in Solid Tumors

P06.01 - Bispecific antibody-driven synthetic agonistic receptor - transduced T cells mediate specific and conditional therapy in melanoma cancer models
Mohamed-Reda Benmabarek, Munich, Germany

P06.03 - C-C chemokine receptor 8 tumor-directed recruitment enables CAR T cells to reject solid tumors
Bruno L. Cadilha, München, Germany

P06.05 - IDO1-deleted CAR T cells show improved therapeutic efficacy in murine pancreatic cancer models
Anne Senz, München, Germany

P06.06 - Adoptive cell therapy of triple negative breast cancer with redirected Cytokine-Induced Killer cells
Annaverda Ventura, Padova, Italy

P06.07 - CXCR6 expression enhances accumulation of anti-mesothelin CAR T cells at the tumor site and their therapeutic efficacy in pancreatic cancer xenografts
Adrian Gottschlich, Munich, Germany

P06.09 - Anti-hPSMA CAR engineered NK-92 cells: An off-the-shelf cellular therapeutic for targeted elimination of prostate cancer cells
Alessandro Penna, Padova, Italy

P06.10 - Short term inhibition of checkpoint proteins increases ex vivo expansion of tumour infiltrating lymphocytes in high grade serous ovarian cancer
Caitlin Waddell, Manchester, United Kingdom

P06.11 - Immunotargeting of CD98hc for Elimination of Radioresistant Head and Neck Squamous Cell Carcinoma
Ayse Küseer, Dresden, Germany

P06.12 - Combination therapy of CAR-NK cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo
Michael Burger, Frankfurt, Germany
POSTER PRESENTATIONS

P06.13 - A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells
Michael Burger, Frankfurt, Germany

P06.14 - Characterization of tumor-infiltrating T cells by highly multiplexed immunofluorescence imaging
Elvira Criado-Moronati, Bergisch Gladbach, Germany

Dong Liu, Branford, United States

P07 - Cell Therapy in Haematologic Diseases

P07.01 - CD19 CAR T-cells for relapsed/refractory Diffuse Large-B-Cell Lymphoma: Real-world data from LMU Munich
Veit Bücklein, Munich, Germany

P07.02 - High-affinity TCRs specific for Cancer Testis Antigens as a therapy for multiple myeloma and solid tumors
Marije de Rooij, Leiden, Netherlands

P08 - Combination Therapy

P08.01 - Low-dose Checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSI low, PD-L1 under 1%, TMB low) - A single-institution experience from 2015 to 2020
Ralf Kleef, Vienna, Austria

P08.03 - Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy
Charlotte Pilard, Liège, Belgium

P08.04 - Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINDREC): a prospective randomized, open-label, multicenter, phase II clinical trial
Johannes Laengle, Vienna, Austria

P09 - Young Researchers Session

P09.01 - Adoptive cell therapy of hematological malignancies using Cytokine-Induced Killer cells retargeted with monoclonal antibodies
Anna Dalla Pietà, Padua, Italy

P09.02 - Mapping and tackling tumor and chemotherapy-induced immune suppression in breast cancer sentinel lymph nodes
Natasa Prokopi, Amsterdam, Netherlands

P09.03 - Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma
Johannes Hildebrand, Munich, Germany

P09.04 - Oncolytic H5N1 influenza strain displays superior therapeutic properties independent of immuno-stimulatory interleukin-2 transgene expression
Julijan Fablija, Vienna, Austria
POSTER PRESENTATIONS

P09.05 - Immunogenicity induced by the academic Chimeric Antigen Receptor CAR19 (ARI-0001) in patients with CD19-positive relapsed/refractory B-cell malignancies recruited into the CART19-BE-01 clinical trial
Nela Klein-González, Barcelona, Spain

P09.07 - An immune modulatory vaccine targeting CCL22 promotes anti-tumor immunity
Inés Lecoq, København, Denmark

P09.08 - Clinical-grade manufacturing of ROR1 CAR T cells using a novel virus-free protocol
Katrin Mestermann, Würzburg, Germany

P09.09 - PD-1 checkpoint blockade for treatment of mucormycosis and invasive aspergillosis in a stem cell transplant recipient
Niklas Mueller, Munich, Germany

P09.10 - Local immunotherapy of brain cancer harnessing high-retention Fc-fusion constructs
Linda Schellhammer, Schlieren, Switzerland

P09.11 - TLR3 suppresses colorectal carcinogenesis, presumably through up-regulation of T-cell attracting CXC chemokines
Anna Sichler, München, Germany

P09.12 - Bifunctional SIRPα-CD123 fusion antibody for the elimination of acute myeloid leukemia stem cells
Siret Tahk, Munich, Germany

P09.13 - Optimization of a GMP-grade large-scale expansion protocol for Cytokine-Induced Killer cells using gas-permeable static culture flasks.
Annavera Ventura, Padua, Italy

P09.14 - Blocking counterregulation of unfolded protein response by targeted protein synthesis inhibition produces highly synergistic cell death in several cancer entities
Franziska Gsottberger, Erlangen, Germany

P09.15 - Targeting the stroma to enhance effector memory T cell infiltration and anti-tumor response to anti-PD1 antibody in pancreatic ductal adenocarcinoma
Arsen Osipov, Baltimore, United States
SCIENTIFIC INFORMATION

Session Structure for Live Presentations
All sessions include pre-recordings as well as a live component. We want to make sure to retain as much human interaction as possible. Prior to the sessions, all lectures are recorded and uploaded to our system. They need to be of an exact length to ensure smooth development of the sessions. At the scheduled timeslot of the session, the chairperson of the session will open the session and introduce the speakers. Then the recording of the first lecture will be played. At all times there is a live-chat available, where all participants can contribute to the session or ask questions which will be monitored by the moderator. After each lecture, there is some time reserved for a discussion with the chairpersons. Lecturers and chairpersons therefore are online at the scheduled timeslot and will discuss questions from the audience.

Commercial Disclosure information
Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g., owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

Speaking Time
The chairpersons of live sessions will be strict in allowing no more than the time allotted to discussions following the pre-recorded presentations. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion.

On-Demand Talks & e-Poster Presentations
On-Demand Talks and e-Poster Presentations can be viewed by participants “on-demand”, which means that individual presentations do not have dedicated times at which they can be viewed – they can be viewed at any time. Authors of e-Poster presentations can be contacted via a messaging system on the conference platform as of October 2, 2020.

Availability of presentations during and after the Conference
All on-demand and e-poster presentations will be available (for registered participants only) on the virtual platform on the conference days and remain there for review until October 17, 2020.
All live presentations will be moved to the on-demand section after October 3, 2020 and remain available there for review (for registered participants only) until October 17, 2020.
Immunotherapy represents a turning point in personalized and targeted treatment of cancer. In spite of great successes, a substantial proportion of patients present primary or developed therapeutic resistance. Furthermore, approaches such as immune checkpoint inhibition can be associated with immune-related adverse events, with autoimmune manifestations ranging from chronic to acute. Also, the use of adoptive T-cell therapy can be associated with excessive immune activation leading to cytokine release syndrome and neurotoxicity. Hence, there is an unmet clinical need for biomarkers that are informative on therapy outcome, long term prognosis, and the risk of immune-related toxicity. Given the complexity of the immune system, such biomarkers should be comprehensive while still readily available for simple implementation into clinical practice. Cytokine profiling in peripheral blood fulfills this requirement but relies on accurate and reproducible assays to ensure consistency of measurement at baseline, over the course of treatment and post-therapy. The Ultra-sensitive Simoa® planar technology (SP-X Imaging and Analysis System) can be used to measure healthy levels of up to 10 key cytokines (Th1/Th2/Th17) in one multiplex assay, allowing for accurate quantitation well above the assay limit of detection; an essential property for robust immune-monitoring of cancer patients. In this presentation, we will discuss how researchers have applied this technology to uncover biomarkers predictive of treatment response, as well as provide new insights into cancer immuno-pathogenesis. The SP-X allows measurement of baseline and early changes of cytokine profiles that can evolve into severe immune-related adverse events, or that can lead to cytokine release syndrome, and therefore can be implemented as a powerful tool in the development of safe and personalized cancer therapies.
LIVE SATELLITE SYMPOSIUM

Saturday, October 3, 2020
11.45 - 12.15 hrs

Lunaphore Satellite Symposium

Rapid hyper-plex staining and simultaneous imaging for immunophenotyping of tissue sections
Diego Dupouy, Lausanne, Switzerland

The simultaneous detection of biomarkers on tissue samples plays a fundamental role in the study of the tumor microenvironment. Multiplexed immunofluorescence tools have demonstrated to be key enablers in these endeavors. Available techniques to perform high-plex staining require intensive manual handling, are highly time consuming, or require special labeling of primary antibodies. Here we present a highly automated, extremely rapid hyper-plex approach to stain and image tissue samples using label-free primary antibodies in combination with off-the-shelf fluorescently labeled secondary antibodies.

ON-DEMAND SATELLITE SYMPOSIUM

nanoString Satellite Symposium

Rational: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with very poor outcome. Most PDAC patients die within the first two years, and only a small subgroup of patients survive for many years. So far, factors and pathways underlining long-term survivorship in PDAC are not known. In a previous study we showed that high CD8/FoxP3 ratio is associated with a favorable outcome. Therefore, we aimed to reveal the immune-related key players that drive the long-term survivorship in PDAC patients.

Methods: The immune-related gene expression profiles of 10 PDAC patients who survived for ≥ 5 years was compared to that of 10 PDAC patients who survived for ≤6 months. Samples were profiled using the PanCancer Immune Profiling Panel of nanoString technology. Subsequently, a subgroup of samples was measured by the GeoMx Digital Spatial Profiler (DSP) to determine the spatial location of the immune cells.

Results: The immune microenvironment in long-term survivors was altered differentially than that of the short-term survivors. B cells were found to be highly expressed in long-term survivors by gene expression profile. The presence of B cells was confirmed by the GeoMx DSP at the protein level. B cells infiltrated to the stroma together with T cells and antigen presenting cells in long-term survivors.

Conclusion: This is the first comprehensive study that compares the expression and the spatial infiltration of immune cells in long-term survivors PDAC patients. Our data demonstrate that long-term survivorship of PDAC patients is influenced by the presence of B cells in the tumor microenvironment. The role of B cells in PDAC disease is controversial. However, our study supports that B cells interact with other compartments of the immune system and drive long-term survivorship in PDAC patients.
GENERAL INFORMATION

In alphabetical order.

Cancellations and Refunds
Registration fees may be refunded if written cancellation has been received as follows:
– until August 16, 2020: full refund
– between August 17 – September 8, 2020: 50% refund
– from September 17, 2020: no refund
The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.
No exceptions to the refund policy can be made, including health or family issues. By registering for ITOC7, participants agree that neither the organising committee nor the congress office assume any liability whatsoever.
Refunds will be made after October 3, 2020

Certificate of Attendance
Confirmations of attendance will be issued to all registered participants and sent via e-mail.

CME Credits
The “7th ImmunoTherapy of Cancer Conference” taking place virtually was granted a total of 10 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Functionality of the virtual platform
The conference organiser’s subcontractors provide a high level of availability of their network, cannot however give any guarantee that their network will operate without any interruptions or malfunctions. No assurances or guarantees can be given about the availability, quality, operation or support services for data traffic, on the networks, or lines of the participant’s Internet provider. The conference organiser is not liable if the provision of the services is interrupted, partially restricted, or impossible as a result of force majeure. Force majeure is for example considered natural phenomena of significant intensity (avalanches, floods, etc.), conflicts, terrorism, strikes, unexpected official restrictions, power cuts, computer viruses, worms, Trojan horses etc.

Language
The official language of the workshop is English (no simultaneous translation).

Liability
In registering for ITOC7, participants agree that neither the organising committee nor the congress office assume any liability whatsoever. The organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the Virtual Conference
October 2, 2020: 08.45 – 18.00 hrs CEST
October 3, 2020: 08.15 – 15.30 hrs CEST
All Live Talks, On-Demand Talks and e-Poster presentations will be available in the On-Demand Section after the conference as of October 4, 2020 until October 17, 2020
Join us at iTOC7
Saturday 3 October 09:00 CET

With a special talk by:

Dr. Raza Ali
CRUK Clinician Scientist Fellow, CRUK Cambridge Institute

Imaging Mass Cytometry to Understand Intercellular Organisation of the Microenvironment in Breast Cancer
GENERAL INFORMATION

In alphabetical order.

Presentations
All presenters are requested to upload their pre-recorded presentations on the virtual platform until September 27, 2020. Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts. If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

Registration Details
Registration Fees in EUR (all fees include 20% Austrian VAT)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academia</td>
<td>EUR 200,-</td>
</tr>
<tr>
<td>Junior Participant</td>
<td>EUR 100,-</td>
</tr>
<tr>
<td>Industry</td>
<td>EUR 300,-</td>
</tr>
<tr>
<td>Press/Media</td>
<td>no fee, but registration is mandatory</td>
</tr>
</tbody>
</table>

The indication of your VAT number is mandatory in case you choose a reverse charge fee!

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academia Reverse</td>
<td>EUR 166.67,-</td>
</tr>
<tr>
<td>Junior Participant</td>
<td>EUR 83.33,-</td>
</tr>
<tr>
<td>Industry Reverse</td>
<td>EUR 250,-</td>
</tr>
</tbody>
</table>

(1) The “Junior Participant” registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration either by fax to +43 1 405 13 83 918 or upload a jpeg, jpg, gif, bmp or png.

(2) A Press ID confirming your status must be provided at the moment of your registration either by fax to +43 1 405 13 83 918 or upload a jpeg, jpg, gif, bmp or png.

Payments should be made without charges to the beneficiary. Any bank charges will be claimed. Clearly state the participant’s name(s) and the invoice number on the bank transfer.

Please be informed, that due to the transition to a virtual meeting, Creditcard payment is preferred. As of September 22, 2020 ONLY creditcard payment will be possible. Thank you for your understanding.

What is covered by the registration fee?
Admission to all scientific sessions (Live, On-Demand, e-Poster)
Abstract book and programme (both online)

Cancellations:
Please note that only written cancellations addressed to ITOC c/o Vienna Medical Academy GmbH, Alser Straße 4, 1090 Vienna, Austria either per E-Mail: itoc@medacad.org or Fax: +43 1 405 13 83 918 can be accepted.
The following rules apply:
- until August 16, 2020: full refund
- from August 17 to September 16, 2020: 50% refund
- as of September 17, 2020: no refund

Twitter
The 7th ImmunoTherapy of Cancer Conference is present on Twitter @ITOCconference.
We invite you to follow us on Twitter, engage and discuss with your colleagues.
Advance your drug candidate

Our expertise across the complete value chain can help you advance your drug candidate

KLIFO is an international drug development consultancy with a high-level of expertise, capability and flexibility for creating solutions and value for pharmaceutical, biotech and med-tech companies.

We offer cross-disciplinary solutions within product development, delivering both strategic consultancy and operational services. All our people have significant pharmaceutical and biotech industry experience.

KLIFO is actively involved in developing cancer immunotherapy agents for several international biotech companies. Our know-how and knowledge within this field is broad and expanding. We provide guidance on how to bring your molecule from the lab to the patient, and we are ready to fill in where you need competence and resources.

Our experts can support your product assets across CMC, regulatory and clinical strategies. We tailor our effort to meet your needs.

KLIFO.com
ACKNOWLEDGEMENTS

The organisers gratefully acknowledge the support of the following institutions and companies:
(please visit our [WEBSITE](https://www.itoc-conference.eu) for detailed information on the companies)
ACKNOWLEDGEMENTS

The organisers gratefully acknowledge the support of the following institutions and companies:
(please visit our WEBSITE for detailed information on the companies)
THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

CONFERENCE MANAGEMENT
WMA GmbH
Catherine Tomek
itoc@medacad.org

SPONSORING MANAGEMENT
Rose International
Flora van Laer
fvanlaer@rose-international.com

www.itoc-conference.eu